|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 558.00 CHF | -0.46% |
|
+3.79% | +3.76% |
| 14/01 | Lonza Group AG Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 10:30 AM | |
| 18/12 | Swiss trade surplus at CHF 3.841 bln in November | RE |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 4.29 | 3.42 | 5.13 | 5 | 4.14 | |||||
Return on Total Capital | 5.73 | 4.54 | 6.71 | 6.61 | 5.55 | |||||
Return On Equity % | 10.89 | 8.1 | 11.89 | 6.49 | 6.74 | |||||
Return on Common Equity | 10.97 | 8.14 | 11.94 | 6.52 | 6.77 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 41.33 | 39.01 | 39.18 | 35.77 | 36.67 | |||||
SG&A Margin | 18.54 | 16.56 | 15.51 | 13.99 | 15.64 | |||||
EBITDA Margin % | 30.92 | 24.16 | 30.5 | 28.51 | 27.18 | |||||
EBITA Margin % | 25.29 | 18.41 | 24.67 | 22.52 | 20.66 | |||||
EBIT Margin % | 21.52 | 15.64 | 22.29 | 20.38 | 18.42 | |||||
Income From Continuing Operations Margin % | 16.24 | 12.52 | 19.57 | 9.75 | 9.69 | |||||
Net Income Margin % | 19.28 | 54.43 | 19.52 | 9.74 | 9.67 | |||||
Net Avail. For Common Margin % | 16.19 | 12.46 | 19.52 | 9.74 | 9.67 | |||||
Normalized Net Income Margin | 12.06 | 8.37 | 13.04 | 11.97 | 9.85 | |||||
Levered Free Cash Flow Margin | -26.05 | 19.95 | -15.88 | 3.2 | 1.05 | |||||
Unlevered Free Cash Flow Margin | -25.15 | 20.79 | -15.28 | 4.01 | 2.34 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.32 | 0.35 | 0.37 | 0.39 | 0.36 | |||||
Fixed Assets Turnover | 1.22 | 1.31 | 1.15 | 1.05 | 0.87 | |||||
Receivables Turnover (Average Receivables) | 6.12 | 6.58 | 5.95 | 5.81 | 5.41 | |||||
Inventory Turnover (Average Inventory) | 2.09 | 2.5 | 2.28 | 2.53 | 2.51 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 1.55 | 2.51 | 1.86 | 1.77 | 1.52 | |||||
Quick Ratio | 0.43 | 1.83 | 1.21 | 1.11 | 0.96 | |||||
Operating Cash Flow to Current Liabilities | 0.36 | 0.51 | 0.33 | 0.5 | 0.36 | |||||
Days Sales Outstanding (Average Receivables) | 59.84 | 55.43 | 61.35 | 62.79 | 67.64 | |||||
Days Outstanding Inventory (Average Inventory) | 174.9 | 145.88 | 160.08 | 144 | 145.59 | |||||
Average Days Payable Outstanding | 58.29 | 39.4 | 42.7 | 42.27 | 39.92 | |||||
Cash Conversion Cycle (Average Days) | 176.45 | 161.91 | 178.73 | 164.52 | 173.32 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 55.77 | 27.99 | 24.26 | 32.93 | 55.69 | |||||
Total Debt / Total Capital | 35.8 | 21.87 | 19.52 | 24.77 | 35.77 | |||||
LT Debt/Equity | 43.86 | 25.76 | 17.39 | 30.54 | 50.23 | |||||
Long-Term Debt / Total Capital | 28.15 | 20.12 | 14 | 22.98 | 32.27 | |||||
Total Liabilities / Total Assets | 52.29 | 40.32 | 38.55 | 43.54 | 52.42 | |||||
EBIT / Interest Expense | 12.76 | 10.44 | 20.1 | 13.69 | 8.24 | |||||
EBITDA / Interest Expense | 18.74 | 16.58 | 28.17 | 19.62 | 12.45 | |||||
(EBITDA - Capex) / Interest Expense | 7 | 0.52 | 1.71 | 3.14 | 3.05 | |||||
Total Debt / EBITDA | 2.7 | 2.05 | 1.33 | 1.6 | 2.86 | |||||
Net Debt / EBITDA | 2.35 | -0.32 | 0.19 | 0.75 | 1.92 | |||||
Total Debt / (EBITDA - Capex) | 7.22 | 65.45 | 21.92 | 9.97 | 11.64 | |||||
Net Debt / (EBITDA - Capex) | 6.29 | -10.36 | 3.08 | 4.66 | 7.83 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 7.15 | 19.99 | 15.05 | 7.94 | -2.13 | |||||
Gross Profit, 1 Yr. Growth % | 4.78 | 14.18 | 15.54 | -1.44 | 0.33 | |||||
EBITDA, 1 Yr. Growth % | 5.05 | -7.96 | 45.22 | 0.9 | -6.49 | |||||
EBITA, 1 Yr. Growth % | 5.17 | -10.27 | 54.12 | -1.43 | -10.01 | |||||
EBIT, 1 Yr. Growth % | 5.66 | -10.48 | 63.95 | -1.3 | -11.28 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 12.96 | -7.51 | 79.91 | -46.22 | -2.75 | |||||
Net Income, 1 Yr. Growth % | 34.73 | 238.78 | -58.73 | -46.17 | -2.75 | |||||
Normalized Net Income, 1 Yr. Growth % | 6.8 | -14.28 | 79.26 | -0.91 | -19.18 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 12.56 | -7.37 | 80.55 | -45.65 | 0.45 | |||||
Accounts Receivable, 1 Yr. Growth % | -5.8 | 29.79 | 25.43 | -2.14 | 12.6 | |||||
Inventory, 1 Yr. Growth % | -18.39 | 32.13 | 21.19 | -12.86 | 8.96 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | -5.92 | 30.72 | 30.38 | 8.12 | 28.94 | |||||
Total Assets, 1 Yr. Growth % | 4.25 | 14.07 | 5.45 | -2.93 | 17.12 | |||||
Tangible Book Value, 1 Yr. Growth % | -579.57 | 290.75 | 27.68 | -14.37 | -16.04 | |||||
Common Equity, 1 Yr. Growth % | 4.94 | 43.07 | 8.69 | -10.8 | -1.31 | |||||
Cash From Operations, 1 Yr. Growth % | 15.66 | 7.7 | -16.19 | 36.08 | -8.21 | |||||
Capital Expenditures, 1 Yr. Growth % | 17.83 | 45.85 | 40.35 | -9.75 | -16.2 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -281.88 | -196.53 | -191.58 | -121.77 | -67.55 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -264.61 | -204.4 | -184.56 | -128.35 | -42.4 | |||||
Dividend Per Share, 1 Yr. Growth % | 9.09 | 0 | 16.67 | 14.29 | 0 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | -9.81 | 13.39 | 17.49 | 11.44 | 2.78 | |||||
Gross Profit, 2 Yr. CAGR % | -7.53 | 8.94 | 14.86 | 6.72 | -0.56 | |||||
EBITDA, 2 Yr. CAGR % | -3.08 | -0.76 | 15.61 | 21.04 | -2.97 | |||||
EBITA, 2 Yr. CAGR % | -1.88 | -4.14 | 17.6 | 23.25 | -5.94 | |||||
EBIT, 2 Yr. CAGR % | -2 | -4 | 21.15 | 27.21 | -6.56 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 5.39 | 2.21 | 28.99 | -1.64 | -27.68 | |||||
Net Income, 2 Yr. CAGR % | 24.68 | 113.64 | 18.24 | -52.87 | -27.65 | |||||
Normalized Net Income, 2 Yr. CAGR % | -3.79 | -5.7 | 23.96 | 33.28 | -10.65 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 5.55 | 2.11 | 29.32 | -0.94 | -26.12 | |||||
Accounts Receivable, 2 Yr. CAGR % | 1.65 | 10.57 | 27.59 | 10.98 | 4.97 | |||||
Inventory, 2 Yr. CAGR % | -4.67 | 3.84 | 26.54 | 2.76 | -2.56 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 6.74 | 10.89 | 30.55 | 18.73 | 18.07 | |||||
Total Assets, 2 Yr. CAGR % | 1.81 | 9.05 | 9.67 | 1.17 | 6.63 | |||||
Tangible Book Value, 2 Yr. CAGR % | 14.45 | 332.89 | 123.36 | 4.56 | -15.21 | |||||
Common Equity, 2 Yr. CAGR % | 4.69 | 22.53 | 24.7 | -1.54 | -6.18 | |||||
Cash From Operations, 2 Yr. CAGR % | 2.19 | 11.61 | -4.99 | 6.79 | 11.76 | |||||
Capital Expenditures, 2 Yr. CAGR % | 29.98 | 31.1 | 43.08 | 12.55 | -13.03 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 650.01 | 29.28 | -5.98 | -55.35 | -73.58 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 293.42 | 27.79 | -6.04 | -51.04 | -59.78 | |||||
Dividend Per Share, 2 Yr. CAGR % | 4.45 | 4.45 | 8.01 | 15.47 | 6.9 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | -0.29 | -0.81 | 13.94 | 14.22 | 6.72 | |||||
Gross Profit, 3 Yr. CAGR % | 1.57 | -1.07 | 11.1 | 9.15 | 4.55 | |||||
EBITDA, 3 Yr. CAGR % | 4.92 | -4.15 | 12.67 | 10.48 | 10.99 | |||||
EBITA, 3 Yr. CAGR % | 6.98 | -5.6 | 12.29 | 10.88 | 10.89 | |||||
EBIT, 3 Yr. CAGR % | 5.72 | -5.74 | 14.75 | 13.15 | 12.7 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 3.2 | 0.9 | 23.41 | -3.64 | -2.01 | |||||
Net Income, 3 Yr. CAGR % | 7.12 | 73.98 | 23.5 | -9.04 | -40 | |||||
Normalized Net Income, 3 Yr. CAGR % | 9.37 | -8.31 | 16.82 | 15.05 | 12.69 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 0.24 | 1.05 | 23.47 | -3.13 | -0.48 | |||||
Accounts Receivable, 3 Yr. CAGR % | -4.66 | 10.28 | 15.32 | 16.93 | 11.52 | |||||
Inventory, 3 Yr. CAGR % | -1.17 | 6.29 | 9.33 | 11.74 | 4.79 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 3.94 | 14.2 | 17.04 | 22.6 | 22.04 | |||||
Total Assets, 3 Yr. CAGR % | 1.42 | 5.74 | 7.84 | 5.3 | 6.23 | |||||
Tangible Book Value, 3 Yr. CAGR % | -11.1 | 72.34 | 188.15 | 62.26 | -2.82 | |||||
Common Equity, 3 Yr. CAGR % | 3.58 | 16.18 | 17.73 | 11.52 | -1.46 | |||||
Cash From Operations, 3 Yr. CAGR % | 10.35 | 4 | 1.45 | 7.1 | 1.54 | |||||
Capital Expenditures, 3 Yr. CAGR % | 28.54 | 35.07 | 34.11 | 22.71 | 2.01 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 62.63 | 272.52 | 15.25 | -42.27 | -60.01 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 55.23 | 148.55 | 11.36 | -36.98 | -48.47 | |||||
Dividend Per Share, 3 Yr. CAGR % | 2.94 | 2.94 | 8.37 | 10.06 | 10.06 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 3.46 | 5.53 | 6.47 | 3.92 | 9.34 | |||||
Gross Profit, 5 Yr. CAGR % | 9.94 | 7.72 | 6.52 | 1.98 | 6.28 | |||||
EBITDA, 5 Yr. CAGR % | 12.29 | 7.34 | 9.48 | 5.23 | 6.13 | |||||
EBITA, 5 Yr. CAGR % | 16.38 | 8.51 | 10.52 | 5.03 | 4.61 | |||||
EBIT, 5 Yr. CAGR % | 14.26 | 6.52 | 11.06 | 6.27 | 5.7 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 21.45 | 17.6 | 12.83 | -0.12 | -0.34 | |||||
Net Income, 5 Yr. CAGR % | 25.69 | 57.79 | 11.44 | 3.19 | -0.28 | |||||
Normalized Net Income, 5 Yr. CAGR % | 16.06 | 6.97 | 14.32 | 6.48 | 4.94 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 13.18 | 9.71 | 10.99 | 0.25 | 0.55 | |||||
Accounts Receivable, 5 Yr. CAGR % | 5.85 | 8.68 | 7.13 | 10.56 | 11.14 | |||||
Inventory, 5 Yr. CAGR % | 4.93 | 10.85 | 9.1 | 4.86 | 4.41 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 8.7 | 14.24 | 13.86 | 15.99 | 17.45 | |||||
Total Assets, 5 Yr. CAGR % | 18.22 | 19.24 | 4.65 | 3.89 | 7.35 | |||||
Tangible Book Value, 5 Yr. CAGR % | 35.33 | 112.27 | 28.51 | 41.12 | 76.65 | |||||
Common Equity, 5 Yr. CAGR % | 26.13 | 32.86 | 11.56 | 8.74 | 7.51 | |||||
Cash From Operations, 5 Yr. CAGR % | 8.81 | 10.11 | 3.93 | 5.11 | 5.45 | |||||
Capital Expenditures, 5 Yr. CAGR % | 28.36 | 29.66 | 34.17 | 25.56 | 12.78 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 20.65 | 23.04 | 29.34 | 59.45 | -36.06 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 17.36 | 21.28 | 25.7 | 29.77 | -25.9 | |||||
Dividend Per Share, 5 Yr. CAGR % | 3.71 | 1.76 | 4.94 | 7.78 | 7.78 |
- Stock Market
- Equities
- LONN Stock
- Financials Lonza Group AG
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















